Amedisys Statistics
Total Valuation
Amedisys has a market cap or net worth of $3.10 billion. The enterprise value is $3.27 billion.
| Market Cap | 3.10B |
| Enterprise Value | 3.27B |
Important Dates
The last earnings date was Wednesday, April 23, 2025, after market close.
| Earnings Date | Apr 23, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
Amedisys has 32.82 million shares outstanding. The number of shares has increased by 1.48% in one year.
| Current Share Class | 32.82M |
| Shares Outstanding | 32.82M |
| Shares Change (YoY) | +1.48% |
| Shares Change (QoQ) | +1.43% |
| Owned by Insiders (%) | 2.30% |
| Owned by Institutions (%) | 90.39% |
| Float | 32.05M |
Valuation Ratios
The trailing PE ratio is 34.80 and the forward PE ratio is 19.66. Amedisys's PEG ratio is 1.31.
| PE Ratio | 34.80 |
| Forward PE | 19.66 |
| PS Ratio | 1.30 |
| Forward PS | 1.24 |
| PB Ratio | 2.59 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | 14.13 |
| P/OCF Ratio | 13.81 |
| PEG Ratio | 1.31 |
Enterprise Valuation
The stock's EV/EBITDA ratio is 13.39, with an EV/FCF ratio of 14.90.
| EV / Earnings | 36.38 |
| EV / Sales | 1.38 |
| EV / EBITDA | 13.39 |
| EV / EBIT | 15.03 |
| EV / FCF | 14.90 |
Financial Position
The company has a current ratio of 1.29, with a Debt / Equity ratio of 0.36.
| Current Ratio | 1.29 |
| Quick Ratio | 1.23 |
| Debt / Equity | 0.36 |
| Debt / EBITDA | 1.60 |
| Debt / FCF | 2.06 |
| Interest Coverage | 7.48 |
Financial Efficiency
Return on equity (ROE) is 7.15% and return on invested capital (ROIC) is 8.18%.
| Return on Equity (ROE) | 7.15% |
| Return on Assets (ROA) | 6.36% |
| Return on Invested Capital (ROIC) | 8.18% |
| Return on Capital Employed (ROCE) | 12.85% |
| Revenue Per Employee | $124,826 |
| Profits Per Employee | $4,729 |
| Employee Count | 19,000 |
| Asset Turnover | 1.11 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, Amedisys has paid $64.81 million in taxes.
| Income Tax | 64.81M |
| Effective Tax Rate | 43.15% |
Stock Price Statistics
The stock price has increased by +3.71% in the last 52 weeks. The beta is 0.89, so Amedisys's price volatility has been lower than the market average.
| Beta (5Y) | 0.89 |
| 52-Week Price Change | +3.71% |
| 50-Day Moving Average | 92.27 |
| 200-Day Moving Average | 93.67 |
| Relative Strength Index (RSI) | 71.67 |
| Average Volume (20 Days) | 326,375 |
Short Selling Information
The latest short interest is 2.36 million, so 7.20% of the outstanding shares have been sold short.
| Short Interest | 2.36M |
| Short Previous Month | 2.66M |
| Short % of Shares Out | 7.20% |
| Short % of Float | 7.37% |
| Short Ratio (days to cover) | 7.41 |
Income Statement
In the last 12 months, Amedisys had revenue of $2.37 billion and earned $89.84 million in profits. Earnings per share was $2.72.
| Revenue | 2.37B |
| Gross Profit | 1.03B |
| Operating Income | 217.41M |
| Pretax Income | 143.78M |
| Net Income | 89.84M |
| EBITDA | 244.10M |
| EBIT | 217.41M |
| Earnings Per Share (EPS) | $2.72 |
Balance Sheet
The company has $284.88 million in cash and $452.01 million in debt, giving a net cash position of -$167.13 million or -$5.09 per share.
| Cash & Cash Equivalents | 284.88M |
| Total Debt | 452.01M |
| Net Cash | -167.13M |
| Net Cash Per Share | -$5.09 |
| Equity (Book Value) | 1.25B |
| Book Value Per Share | 36.55 |
| Working Capital | 141.93M |
Cash Flow
In the last 12 months, operating cash flow was $224.52 million and capital expenditures -$5.10 million, giving a free cash flow of $219.42 million.
| Operating Cash Flow | 224.52M |
| Capital Expenditures | -5.10M |
| Free Cash Flow | 219.42M |
| FCF Per Share | $6.69 |
Margins
Gross margin is 43.37%, with operating and profit margins of 9.17% and 3.79%.
| Gross Margin | 43.37% |
| Operating Margin | 9.17% |
| Pretax Margin | 6.33% |
| Profit Margin | 3.79% |
| EBITDA Margin | 10.29% |
| EBIT Margin | 9.17% |
| FCF Margin | 9.25% |
Dividends & Yields
Amedisys does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -1.48% |
| Shareholder Yield | -1.48% |
| Earnings Yield | 2.90% |
| FCF Yield | 7.08% |
Analyst Forecast
The average price target for Amedisys is $100.80, which is 6.75% higher than the current price. The consensus rating is "Hold".
| Price Target | $100.80 |
| Price Target Difference | 6.75% |
| Analyst Consensus | Hold |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
The last stock split was on December 5, 2006. It was a forward split with a ratio of 1.33333:1.
| Last Split Date | Dec 5, 2006 |
| Split Type | Forward |
| Split Ratio | 1.33333:1 |
Scores
Amedisys has an Altman Z-Score of 4 and a Piotroski F-Score of 6.
| Altman Z-Score | 4 |
| Piotroski F-Score | 6 |